| COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (NCT07449936) | EyePoint Pharmaceuticals, Inc. | 2026-02-16 |
| CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (NCT07449923) | EyePoint Pharmaceuticals, Inc. | 2026-02-09 |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 (NCT06683742) | EyePoint Pharmaceuticals, Inc. | 2024-11-27 |
| A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 (NCT06668064) | EyePoint Pharmaceuticals, Inc. | 2024-10-22 |
| Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (NCT06099184) | EyePoint Pharmaceuticals, Inc. | 2024-01-15 |
| Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR) (NCT05383209) | EyePoint Pharmaceuticals, Inc. | 2022-09-28 |
| A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2) (NCT05550363) | EyePoint Pharmaceuticals, Inc. | 2022-09-01 |
| Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (NCT05381948) | EyePoint Pharmaceuticals, Inc. | 2022-06-30 |
| Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (NCT05191706) | EyePoint Pharmaceuticals, Inc. | 2022-01-04 |
| Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert (NCT05070728) | EyePoint Pharmaceuticals, Inc. | 2021-10-13 |
| First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD) (NCT04747197) | EyePoint Pharmaceuticals, Inc. | 2021-01-20 |
| Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 (NCT04511650) | EyePoint Pharmaceuticals, Inc. | 2020-10-21 |
| DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001 (NCT04290676) | EyePoint Pharmaceuticals, Inc. | 2019-11-13 |